Exec Edge - 2025-07-17 18:58
By Daniella Parra Lisata Therapeutics said it has been granted a new composition of matter patent for its lead drug candidate, certepetide, offering the highest level of IP protection by covering the drug’s unique chemical structure, how it’s made, and how it’s used to treat solid tumor cancers, they said. Certepetide is an investigational […]